In the run-up to his first anniversary as CEO of Sanofi, Chris Viehbacher talked about wresting control from scientists who didn't want to look outside for new ideas or products. "I think we have been able to open up the walls of the company," Viehbacher told the Financial Times in November.
There's no greater example of Viehbacher's push than the billion-dollar expansion of Sanofi's R&D relationship with antibody platform firm Regeneron Pharmaceuticals Inc., announced in November. [See Deal] The...